Indian Pharmaceutical Market, 2006-2011

Questions: Discounts, Updates etc.

Pages: 143

Price (Single): £1,499

Price (Departmental): £2,999

Price (Company): £4,999

Publication Date: 2006-06-12

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

The Indian pharmaceutical market is the 15th largest individual market by sales, but the 4th by volume of product. With domestic drug sales of almost $5 billion, Indian companies have also developed a considerable service industry for the global pharmaceutical market. However the Indian pharmaceutical market looks set for considerable change.

For many years the Indian pharmaceutical market has been seen as a no go area for the R&D based MNCs. The market became dominated by copied generic drugs produced at low-cost by Indian companies. One full year after the introduction of the WTO TRIPS and in the midst of the practical implications of ensuring compliance with product patents, how is the Indian pharmaceutical industry facing up to new regulations to its market?

Indian pharmaceutical companies are able to provide FDA approved facilities for the complete range of services for drug development. R&D services, API sourcing, finished formulation manufacture and clinical trials can all be completed in India, at less cost than in many developed markets. The leading Indian pharmaceutical companies are also beginning to increase market presence and market share in the US and EU markets.

Pivotal period of changeâ€¦

The Indian pharmaceutical market is entering a pivotal period of change. Although it is unlikely to see significant growth before 2011, visiongain expects extensive company activity as the leading Indian pharmaceutical companies strive towards international competitiveness. Global pharmaceutical companies have already begun to take advantage of the changing regulatory and economic conditions in India. The following five years will see further merger and acquisition activity, including key overseas acquisitions.

The Leading Pharmaceutical Companies Within India

Rank Company
1. Ranbaxy Laboratories
2. Cipla
3. Dr Reddy's Laboratories
4. Sun Pharmaceuticals
5. Nicholas Piramal
6. Zydus Cadila
7. Biocon
8. Glenmark Pharmaceuticals
9. Wockhardt Ltd
10. Orchid Chemicals

Why you should buy this report

Significant change is imminent within and from the Indian pharmaceutical market. Global MNCs cannot afford to ignore the cost advantages that the Indian market offers.
Key companies are examined, recent histories summarised and strategies outlined to provide indications of potential strengths.
The key IP changes resulting from the acceptance of the WTO TRIPS are outlined.
This report considers the latest financial and anecdotal information from the Indian pharmaceutical market to enable the most accurate assessment of the medium-term future potential of this $5 billion market.

1. Executive Summary

1.1 The Indian Pharmaceutical Market Will Be Worth $7.58 Billion By 2011
1.2 Aims, Scope and Format of the Report
1.3 Research Methodology

2. Introduction

3. The Indian Healthcare System

3.1 Organisation of the Indian Healthcare System

3.2 Emphasis on Local Participation
3.3 State Financed Research and Technology
3.4 Clean Water and Sewage Disposal
3.5 Finance and Resources
3.6 Physical infrastructure
3.7 Indian Healthcare Neglects the Poor
3.8 The Indian Market for Healthcare
3.9 Indian Healthcare Statistics
3.10 India's Healthcare Market Has a High Potential
3.11 The High Price of Being Ill in India
3.12 The Disease Burden in India
3.13 HIV Will Grow
3.14 TB Is the Biggest cause of Death in India
3.15 Maternal, Perinatal and Childhood Conditions Have the Highest Burden of Disease
3.16 Malaria is Still Highly Prevalent in India
3.17 Non-communicable Conditions and the Rise of Western Diseases in India
3.18 Cardiovascular Disease is On the Rise
3.19 Diabetes Will Increase
3.20 Incidence of Cancer Will Increase
3.21 Mental Health Disorders
3.22 Asthma and COPD
3.23 Blindness Prevalence Will Remain Unchanged
3.24 The Drug Price Control Order (DPCO)
3.25 A List of the Key Pharmaceutical Organisations in India

4. The Indian Economy

4.1 IMF Forecasts Continuing Positive Economic Growth

4.2 Life Expectancy is Still Low in India Compared to the West
4.3 Technical Labour Force Remains Important
4.4 Indian Agriculture Is Inefficient
4.5 Indian Industry is Set for High Growth Levels
4.6 The Services Sector Will Also Grow
4.7 The Indian Rupee
4.8 India's Growing Future
4.9 Poverty Is Still High in India
4.10 Steps Taken to Reduce Bureaucracy and Corruption 4.11 Occupation and Unemployment

5. Indian IP, WTO and TRIPS

5.1 Anticipation of an Open Indian Market
5.2 Indian Patent Act Allowed Only Process Patents
5.3 TRIPS Agreement Changes Format of the Indian Pharma Market
5.4 Intermediary Measures Should Smooth Transition
5.5 The Mailbox System
5.6 Does the Drug Price Control Order Help or Hinder?
5.7 Predicted Consequences of India's New Pharmaceutical IP System
- 5.7.1 Potential Advantages for the Indian Pharmaceutical Market
- 5.7.2 Potential Disadvantages for the Indian Pharmaceutical Market

6. The Indian Pharmaceutical Market
- 6.1 The Indian Pharmaceutical Market Has Shown Historical Growth
- 6.2 Generics Dominate Branded Products on the Indian Pharmaceutical Market
  - 6.2.1 Antibiotics Lead the Indian Market
  - 6.2.2 Volume Greater Driver than New Products
- 6.3 India's OTC Market
- 6.4 Infrastructure Weak - Distribution Vital
- 6.5 Counterfeiting
- 6.6 The Future of the Indian Pharmaceutical Market Looks Positive
- 6.7 The Localised Nature of the Indian Pharmaceutical Market Will Alter

7. The Impact of Indian Companies on the World Pharma Market

7.1 Contract Manufacturing and R&D Activity
7.2 API Sourcing

8. Clinical Trials Industry

8.1 A SWOT Analysis of Outsourcing Clinical Trials to India
8.2 Many Factors are Considered When Deciding Clinical Trial Location but Quality of Data Should Be Paramount
8.3 India as a Model for Rapid Growth in the Clinical Trials Industry
8.4 Expanding Pharmaceutical Investment in India is Led by Clinical Trials
8.5 Changes to the Law Have Caused Rapid Growth of Clinical Research
8.6 Rapid Recruitment Is Driven by a Large Patient Population and an Organised Healthcare System
8.7 Ethical Considerations in India
8.8 What Is India Doing to Promote Clinical Research?
8.9 Forecast: What Is the Future of Indian Clinical Research?

9. SWOT Analysis of the Indian Pharmaceutical Market

10. An Overview of the Leading Indian Pharmaceutical Companies

10.1 Ranbaxy

10.1.1 Ranbaxy Wins Lipitor Patent Decision in Austria
10.1.2 R&D Investment Offers Another Strategy
10.1.3 Ranbaxy's M&A Activity
10.1.4 Ranbaxy Summary

10.2 Cipla
- 10.2.1 Will Cipla Struggle to Adapt?
- 10.2.2 Cipla Summary
10.3 Dr Reddy's
- 10.3.1 US Market Generic Competition Hits Dr Reddy's
- 10.3.2 Dr Reddy's Active with M&A
- 10.3.3 Dr Reddy's Pipeline
- 10.3.4 Dr Reddy's Summary
10.4 Other Leading Companies
- 10.4.1 Nicholas Piramal Adopts Co-operative Strategy
- 10.4.2 Wockhardt Achieves Notable Successes in US and UK
- 10.4.3 Glenmark Pharmaceuticals - US Market Activity
- 10.4.4 Orchid Develops From Alliance-based to Brand Market Presence
- 10.4.5 Supporting Companies Seek Developing Strategies
10.5 Conclusion

11. Conclusion â€“ Key Aspects of the Indian Pharmaceutical Industry

List of Tables and Figures

Table 3.1 Access to Safe Water and Sewage Disposal, 2005

Table 3.2 Indian Healthcare Expenditure Statistics, 2005

Table 3.3 Indian Health Facilities and Human Resources, 2004

Table 3.4 Indian Disease Burden, 1998

Table 4.1 Indian GDP Leveles, 2005

Table 4.2 Population, General Health and Economic Statistics, 2005

Table 6.1 The Top 20 Pharmaceutical Markets by Country, 2005

Table 6.2 The Leading Indian Pharmaceutical Companies, 2005

Table 6.3 Generic Market Share By Value and Volume, 2005

Table 6.4 Revenue ($m) and Growth Rate (%) of the Leading Drugs on the Indian Market,2005

Table 6.5 Sectors Contributing to the Overall Growth of the Indian Pharmaceutical Market, 1995-2002

Table 6.6 Forecast Revenue of the Indian Pharmaceutical Market, 2004-2011

Table 7.1 API and Formulation Production ($m) in India, 2003-2005

Table 7.2 API, Formulation and Intermediate Imports, ($m) 2003-2005

Table 7.3 API and Formulation Exports ($m), 2003-2005

Table 7.4 Comparable Cost Advantages (%) from India's Pharmaceutical Market, 2005

Table 7.5 Recent MNC Infrastructure Activity in the Indian Pharmaceutical Market, 2005

Table 8.1 SWOT Analysis of Outsourcing Clinical Trials to Developing Countries, 2006

Table 8.2 Estimated Cost ($m) of Clinical Trials in the US and India, 2006

Table 8.3 Comparison of Disease Prevalence (m) in the US and India

Table 9.1 SWOT Anaylsis of the Indian Pharmaceutical Market, 2006

Table 10.1 The Leading Indian Pharmaceutical Companies

Table 10.2 Leading Companies in the Indian Pharma Market by Revenue ($m), 2005

Table 10.3 Leading Indian Pharmaceutical Companies

by Total Revenue ($m), 2005

Table 10.4 Ranbaxy's Leading Products by Revenue, 2005

Table 10.5 Ranbaxy Revenue Generation by Region, 2005

Table 10.6 Pipeline Projects, Ranbaxy, 2006

Table 10.7 Cipla's Leading Products by Revenue, 2005

Table 10.8 Cipla Revenue Generation by Region, 2005

Table 10.9 Dr Reddy's Leading Products by Revenue, 2005

Table 10.10 Dr Reddy's Revenue Generation by Region, 2005

Table 10.11 Pipeline Projects, Dr Reddyâ€™s, 2006

Figure 1.1 Forecast Revenue ($m) of the Indian Pharmaceutical Market, 2004-2011

Figure 6.1 Indian Pharmaceutical Market Revenue ($bn), 2000-2005

Figure 6.2 Indian Drug Revenue ($m) By Therapeutic Class, 2005

Figure 6.3 Indian Drug Growth Rate (%) By Therapeutic Class, 2005

Figure 6.4 Forecast Revenue ($m) of the Indian Pharmaceutical Market, 2004-2011

Figure 8.1 Factors Affecting Clinical Trial Location

Figure 8.2 Clinical Trial Revenues ($m) in India, 2005-2010

Figure 8.3 Clinical Trial Growth Rates (%) in India, 2005-2010

Figure 10.1 Ranbaxy's Leading Products by Total Revenue Share (%), 2005

Figure 10.2 Ranbaxy Revenue Generation by Region, 2005

Figure 10.3 Cipla Leading Products by Total Revenue Share (%), 2005

Figure 10.4 Cipla Revenue Generation by Region, 2005

Figure 10.5 Dr Reddy's Leading Products by Total Revenue Share (%), 2005

Figure 10.6 Dr Reddy's Revenue Generation by Region, 2005

Figure 11.1 Forecast Revenue for the Indian Pharmaceutical Market, 2006-2011

Other users found this report page using the following search terms: Indian pharmaceutical india pharmaceutical markets indian pharmaceutical market pharma india companies top 20 industry analysis

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Indian Pharmaceutical Market, 2006-2011

Credit Card Details

Invoice Details

Table of Contents